Comparison of mortality rates in patients with carbapenem-resistant Enterobacterales bacteremia according to carbapenemase production: a multicenter propensity-score matched study

• Published in: Scientific reports 2024-01, Vol.14 (1), p.597-597, Article 597
• Main Authors: Baek, Moon Seong, Kim, Jong Ho, Park, Joung Ha, Kim, Tae Wan, Jung, Hae In, Kwon, Young Suk
• Format: Article
• Language: English
• Subjects: 692/308; 692/699; Bacteremia; Carbapenemase; Carbapenems; Enterobacterales; Health risks; Humanities and Social Sciences; Mortality; multidisciplinary; Public health; Science; Science (multidisciplinary)
• ISSN: 2045-2322; 2045-2322
• DOI: 10.1038/s41598-023-51118-9

The spread of carbapenem-resistant Enterobacterales (CRE) poses a public health threat worldwide. We aimed to compare the mortality rates between the carbapenemase-producing (CP) and non-CP CRE bacteremia. We conducted a retrospective cohort study in patients with CRE bacteremia after propensity score (PS) matching. We performed a Kaplan–Meier curve analysis to identify the cumulative hazard for 30-day mortality. There were 318 patients with CRE between January 1, 2018, and December 31, 2022. There were 252 patients with CP-CRE and 66 with non-CP-RE, respectively. Before PS matching, the 30-day mortality rates were 40.9% in the non-CP-CRE group and 53.2% in the CP-CRE group ( p  = 0.097). In patients in the intensive care unit (ICU), the mortality rates were 49.0% in the non-CP-CRE group and 57.1% in the CP-CRE group ( p  = 0.340). After PS matching, the hazard ratio (HR) for mortality in the CP-CRE group was 1.49 (95% confidence interval [CI] 0.74–3.03), p  = 0.266). In ICU patients, the HR of CP-CRE was 1.11 (95% CI 0.36–3.39, p  = 0.860). The Kaplan–Meier curve for 30-day mortality showed no difference in cumulative hazard. After PS matching, there was no difference in 30-day mortality between patients with CP-CRE and non-CP-CRE bacteremia.